Chengdu XianDao: Partner BioAge initiates Phase I clinical study of novel NLRP3 inhibitor BGE-102.

According to news from Chengdu Lead, the company's partner, BioAgeLabs, Inc., recently initiated Phase I clinical trials for the novel and potent NLRP3 inhibitor BGE-102. The lead compound of BGE-102 was selected from Chengdu Lead's DNA-encoded compound library. According to the cooperation agreement between the two parties, Chengdu Lead will receive milestone payments, the specific amount of which has not been disclosed. BGE-102 is an orally bioavailable small molecule NLRP3 inhibitor with a novel structure, high activity, and good brain permeability, developed for the treatment of obesity.